+275.3%
NXPI vs MRNA
+840.0%
-564.7%
-53.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.7% | -3.9% | +3.3% | -0.4% |
| 7D | -3.5% | -17.6% | +14.1% | -2.2% |
| 30D | +10.1% | -5.1% | +15.2% | +10.3% |
| 3M | +9.0% | +220.8% | -211.8% | -5.3% |
| 6M | -12.7% | +321.7% | -334.4% | -27.3% |
| YTD | +17.9% | +601.3% | -583.4% | -8.8% |
| 1Y | +34.9% | +735.2% | -700.3% | +1.9% |
| 3Y | +32.5% | +170.5% | -138.0% | +9.9% |
| 5Y | +27.1% | -14.6% | +41.7% | +11.9% |
| All | +275.3% | +840.0% | -564.7% | +228.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling